DNA Methylation in Lung Cancer: Predictive Biomarkers for Effective Immunotherapy

Area of Science:

• Oncology
• Epigenetics
• Immunology

Background:

• Lung cancer is a major cause of cancer mortality globally.
• Immunotherapy offers promise but benefits only a subset of patients.
• Predictive biomarkers are crucial for personalized lung cancer treatment.

Purpose of the Study:

• To review DNA methylation (DNAm) as a predictive biomarker for immunotherapy in lung cancer.
• To highlight the role of DNAm in immune response and treatment efficacy.
• To discuss integrated epigenetic signatures and liquid biopsies for clinical application.

Main Methods:

• Review of current literature on DNA methylation and lung cancer immunotherapy.
• Analysis of DNAm in immune-related genes and their association with tumor characteristics.
• Evaluation of established and emerging biomarkers for immunotherapy response.

Main Results:

• DNA methylation patterns correlate with tumor phenotype, immune cell infiltration, and response to immune checkpoint inhibitors (ICIs).
• DNAm serves as a key epigenetic biomarker for predicting immunotherapy efficacy.
• Integrated epigenetic signatures and liquid biopsies show potential for clinical use.

Conclusions:

• DNA methylation is a critical epigenetic biomarker for personalizing lung cancer immunotherapy.
• Further research is needed to translate epigenetic biomarkers into clinical practice.
• Optimizing immunotherapy outcomes and reducing adverse events are key future directions.